French biotech DBV Technologies (Euronext: DBV) has returned to the US Food and Drug Administration (FDA) with a new Biologics License Application (BLA) for Viaskin Peanut.
The company claims that this revised application addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December 2018, when DBV voluntarily withdrew its prior BLA submission.
Viaskin Peanut is being developed for the treatment of peanut-allergic in children aged four to 11 years and is DBV’s lead product candidate based on epicutaneous immunotherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze